Iconovo マネジメント

マネジメント基準チェック /24

Iconovoの CEO はJohan Waborgで、 Jan2020年に任命され、の在任期間は 4.83年です。は、会社の株式の0.47%を直接所有しており、その価値はSEK 380.35K 。経営陣と取締役会の平均在任期間はそれぞれ3.3年と5.8年です。

主要情報

Johan Waborg

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	4.8yrs
CEOの所有権	0.5%
経営陣の平均在職期間	3.3yrs
取締役会の平均在任期間	5.8yrs

経営陣の近況

Recent updates

Iconovo AB (publ)'s (STO:ICO) Intrinsic Value Is Potentially 37% Above Its Share Price

Jun 13

Companies Like Iconovo (STO:ICO) Can Afford To Invest In Growth

Apr 13

When Will Iconovo AB (publ) (STO:ICO) Turn A Profit?

Mar 18

Have Iconovo AB (publ) (STO:ICO) Insiders Been Selling Their Stock?

Feb 20

A Look At Iconovo's (STO:ICO) Share Price Returns

Feb 07

CEO（最高経営責任者

Johan Waborg (47 yo)

4.8yrs

在職期間

Mr. Johan Wäborg serves as Chief Executive Officer at Iconovo AB (publ) since 2020.

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Johan Waborg	Chief Executive Officer	4.8yrs	データなし	0.47% SEK 380.3k
Orest Lastow	Co-Founder	4.8yrs	データなし	5.19% SEK 4.2m
Henrik Simonssen	Chief Financial Officer	1.6yrs	データなし	データなし
Mikael Arinder	Vice President of Operations	8.8yrs	データなし	0.12% SEK 98.2k
Josefin Olsen	HR Manager	1.8yrs	データなし	データなし
Carl Forslund	Head of Industrial Design	no data	データなし	データなし
Therese Dahl	Business Controller	1.8yrs	データなし	データなし

3.3yrs

平均在職期間

60yo

平均年齢

経験豊富な経営陣: ICOの経営陣は経験豊富であると考えられます ( 3.3年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Orest Lastow	Co-Founder	11.8yrs	データなし	5.19% SEK 4.2m
Mats Johansson	Director	11.8yrs	データなし	7.86% SEK 6.4m
Gunnar Gardemyr	Independent Chairman of the Board	4.8yrs	データなし	0.20% SEK 166.4k
Kjell Larsson	Member of Scientific Advisory Board	no data	データなし	データなし
Lennart Holm	Member of Business Advisory Board	no data	データなし	データなし
Rikard Roos	Member of Business Advisory Board	no data	データなし	データなし
Ann Gidner	Independent Director	3.8yrs	データなし	データなし
Berndt Axelsson	Independent Director	11.8yrs	データなし	2.01% SEK 1.6m
Björn Andersson	Member of Business Advisory Board	no data	データなし	データなし
Carl Lindgren	Independent Director	1.5yrs	データなし	0.25% SEK 204.8k
Agneta Walhagen	Independent Director	5.8yrs	データなし	0.028% SEK 23.0k

5.8yrs

平均在職期間

63yo

平均年齢

経験豊富なボード: ICOの取締役会は経験豊富であると考えられます ( 5.8年の平均在任期間)。

Iconovo マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Vice President of Operations recently bought kr57k worth of stock

Vice President of Operations recently bought kr80k worth of stock

Independent Director recently bought kr246k worth of stock

Iconovo AB (publ), Annual General Meeting, May 21, 2024

Insufficient new directors

Independent Chairman of the Board recently bought kr190k worth of stock

Recent updates

Iconovo AB (publ) has completed a Composite Units Offering in the amount of SEK 28.653075 million.

New major risk - Revenue and earnings growth

New major risk - Financial position

Third quarter 2024 earnings released: kr0.70 loss per share (vs kr0.97 loss in 3Q 2023)

Iconovo Initiates Development of the GLP-1 Antibody Semaglutide in the Inhaler Iocone Nasal

New minor risk - Share price stability

Price target increased by 12% to kr23.50

New major risk - Market cap size

Should You Investigate Iconovo AB (publ) (STO:ICO) At kr6.68?

Now 21% undervalued after recent price drop

Consensus revenue estimates increase by 17%

Iconovo AB (publ) Develops Intranasally Inhaled Semaglutide in ICOone Nasal for More User-Friendly Treatment of Overweight and Obesity

Vice President of Operations recently bought kr57k worth of stock

Second quarter 2024 earnings released: kr0.60 loss per share (vs kr1.32 loss in 2Q 2023)

Now 21% overvalued after recent price rise

Iconovo AB (publ) to Report Q4, 2024 Results on Feb 27, 2025

Vice President of Operations recently bought kr80k worth of stock

Independent Director recently bought kr246k worth of stock

Now 22% overvalued after recent price rise

Iconovo AB (Publ) Files Patent Application for Inhaled GLP-1 Products and Initiates Development of New Obesity Treatments

Consensus revenue estimates increase by 15%, EPS downgraded

New major risk - Shareholder dilution

Iconovo AB (publ) Receives Patent Protection for Icores in China

Iconovo AB (publ), Annual General Meeting, May 21, 2024

First quarter 2024 earnings released: kr0.69 loss per share (vs kr1.35 loss in 1Q 2023)

New major risk - Revenue and earnings growth

Iconovo AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 18.8 million.

Iconovo AB (publ) to Report Q1, 2024 Results on Apr 25, 2024

New major risk - Market cap size

Insufficient new directors

New minor risk - Profitability

New major risk - Market cap size

Independent Chairman of the Board recently bought kr190k worth of stock

Third quarter 2023 earnings released: kr0.97 loss per share (vs kr1.14 loss in 3Q 2022)

Iconovo AB (publ) Completes Enrollment in Phase I Clinical Trial of Inhaled Oxytocin in ICOone

Iconovo AB (publ) Receives US Patent for Ioccap That Strengthens the Offering for More Customer Collaborations

Iconovo AB (Publ) Provides Earnings Guidance for the Years 2024, 2025, 2026 and 2027

New minor risk - Share price stability

New major risk - Financial position

Second quarter 2023 earnings released: kr1.36 loss per share (vs kr1.38 loss in 2Q 2022)

We're A Little Worried About Iconovo's (STO:ICO) Cash Burn Rate

Price target decreased by 27% to kr63.00

Iconovo AB (publ) Strengthens its Customer Offering in the Novel Pharmaceuticals Business Segment

Iconovo AB (Publ) Announces Appoints Carl Lindgren as Chief Business Development Officer

Independent Director recently sold kr98k worth of stock

Independent Director recently sold kr171k worth of stock

Chief Executive Officer recently bought kr61k worth of stock

Independent Chairman of the Board recently bought kr100k worth of stock

Iconovo AB (publ) to Report Fiscal Year 2022 Results on Feb 08, 2023

Insufficient new directors

Iconovo Receives Approval of New European Patent for Its Single-Use Inhaler ICOone®

Iconovo AB (publ) Announces Executive Changes, Effective April 1, 2023

Iconovo's ICOone Inhaler Platform Receives New Patent Approval in the US

Iconovo Announces Appointment of Nomination Committee

Third quarter 2022 earnings released: kr1.14 loss per share (vs kr0.43 loss in 3Q 2021)

Iconovo AB (publ) Conducts a User Study to Assess the Handling of its ICOone Nasal Inhaler

Here's Why We're Watching Iconovo's (STO:ICO) Cash Burn Situation

Second quarter 2022 earnings released: kr1.38 loss per share (vs kr0.85 loss in 2Q 2021)

Iconovo AB (Publ) Announces First Patent Grant in Japan for It's ICOone

Chief Executive Officer recently bought kr69k worth of stock

Director recently bought kr258k worth of stock

Chief Executive Officer recently bought kr104k worth of stock

Price target increased to kr140

Full year 2021 earnings: EPS and revenues miss analyst expectations

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Iconovo AB (publ) Announces Completion of Comparative Clinical Study of Icores Budesonide/Formoterol and Symbicort Turbuhaler

Chief Financial Officer recently bought kr53k worth of stock

Director recently bought kr78k worth of stock

No longer forecast to breakeven

マネジメント基準チェック /24